Pharming Group N.V. (DE:PHGN)
XETRA:PHGN
PHGN Stock Chart & Stats
€1.42
€0.01(1.21%)
At close: 4:00 PM EST
€1.42
€0.01(1.21%)
Day’s Range― - ―
52-Week Range€0.67 - €1.78
Previous CloseN/A
Volume0.00
Average Volume (3M)11.21K
Market Cap
€1.01B
Enterprise Value€1.12B
Total Cash (Recent Filing)€179.88M
Total Debt (Recent Filing)€115.79M
Price to Earnings (P/E)347.8
Beta0.56
Next Earnings
May 07, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding701,404,050
10 Day Avg. Volume3,832
30 Day Avg. Volume11,210
Financial Highlights & Ratios
PEG Ratio-2.75
Price to Book (P/B)3.72
Price to Sales (P/S)2.64
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€405.15M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA reported gross margin near 93% indicates a structurally high-margin product mix (recombinant biologic and specialty oral therapy). Such margins provide durable operating leverage, support cash generation, and help fund R&D and commercialization even if volumes vary.
Strong Commercial Momentum And Upgraded GuidanceSynchronous growth across RUCONEST and Joenja, coupled with an upgraded full-year revenue range, demonstrates scalable commercial execution and diversifies revenue drivers. That cross-product strength improves medium-term visibility and reduces reliance on a single launch or geography.
Improving Cash Generation And Balance SheetA $32m operating cash flow recovery and falling leverage enhance financial flexibility to fund commercialization and late-stage trials. Improved cash generation reduces near-term refinancing risk and supports sustained investment in the rare-disease pipeline.
Bears Say
Volatile Profitability And Cash FlowEarnings and cash flows have oscillated materially over recent years, moving from multi-year profits to losses and only modest recovery in 2025. This volatility weakens predictability for capital allocation, heightens execution risk, and can constrain consistent funding of growth initiatives.
Inconsistent Revenue Trend (2025 Pullback)A roughly 8% revenue decline in 2025 after multi-year growth highlights inconsistent top-line traction. For rare-disease drugs, revenue depends on diagnosis rates, payer coverage and geographic rollouts; uneven progress undermines medium-term scale benefits and margin expansion.
RUCONEST Withdrawal In Certain MarketsWithdrawing RUCONEST from some European markets reduces addressable patient base and signals reimbursement or pricing sustainability issues. Permanent market exits can lower long-term revenue potential and complicate future payer negotiations across geographies.
Pharming Group News
PHGN FAQ
What was Pharming Group N.V.’s price range in the past 12 months?
Pharming Group N.V. lowest stock price was €0.67 and its highest was €1.78 in the past 12 months.
What is Pharming Group N.V.’s market cap?
Pharming Group N.V.’s market cap is €1.01B.
When is Pharming Group N.V.’s upcoming earnings report date?
Pharming Group N.V.’s upcoming earnings report date is May 07, 2026 which is in 29 days.
How were Pharming Group N.V.’s earnings last quarter?
Pharming Group N.V. released its earnings results on Mar 12, 2026. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of €0.002 by €0.004.
Is Pharming Group N.V. overvalued?
According to Wall Street analysts Pharming Group N.V.’s price is currently Overvalued.
Does Pharming Group N.V. pay dividends?
Pharming Group N.V. does not currently pay dividends.
What is Pharming Group N.V.’s EPS estimate?
Pharming Group N.V.’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group N.V. have?
Pharming Group N.V. has 701,404,050 shares outstanding.
What happened to Pharming Group N.V.’s price movement after its last earnings report?
Pharming Group N.V. reported an EPS of €0.006 in its last earnings report, beating expectations of €0.002. Following the earnings report the stock price went down -4.467%.
Which hedge fund is a major shareholder of Pharming Group N.V.?
Currently, no hedge funds are holding shares in DE:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHGN Company Deck
PHGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all DE:PHGN earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---